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Inhibition of either P2Y12 receptor or the nucleotide-binding oligomerization domain- (NOD-) like receptor pyrin domain
containing 3 (NLRP3) inflammasome provides cardioprotective effects. Here, we investigate whether direct NLRP3
inflammasome inhibition exerts additive effects on myocardial protection induced by the P2Y12 receptor antagonist Ticagrelor.
Ticagrelor (150mg/kg) was orally administered to rats for three consecutive days. Then, isolated hearts underwent an
ischemia/reperfusion (30min ischemia/60min reperfusion; IR) protocol. The selective NLRP3 inflammasome inhibitor INF
(50 μM) was infused before the IR protocol to the hearts from untreated animals or pretreated with Ticagrelor. In parallel
experiments, the hearts isolated from untreated animals were perfused with Ticagrelor (3.70 μM) before ischemia and subjected
to IR. The hearts of animals pretreated with Ticagrelor showed a significantly reduced infarct size (IS, 49 ± 3% of area at risk,
AAR) when compared to control IR group (69 ± 2% of AAR). Similarly, ex vivo administration of INF before the IR injury
resulted in significant IS reduction (38 ± 3% of AAR). Myocardial IR induced the NLRP3 inflammasome complex formation,
which was attenuated by either INF pretreatment ex vivo, or by repeated oral treatment with Ticagrelor. The beneficial effects
induced by either treatment were associated with the protective Reperfusion Injury Salvage Kinase (RISK) pathway activation
and redox defence upregulation. In contrast, no protective effects nor NLRP3/RISK modulation were recorded when Ticagrelor
was administered before ischemia in isolated heart, indicating that Ticagrelor direct target is not in the myocardium. Our results
confirm that Ticagrelor conditioning effects are likely mediated through platelets, but are not additives to the ones achieved by
directly inhibiting NLRP3.
1. Introduction
Ischemic heart disease remains the leading cause of morbid-
ity in the Western world, and the number of deaths from
acute myocardial infarction (AMI) is also rapidly rising in
the developing world. Although restoration of early blood
flow to the ischemic myocardium with thrombolysis is pres-
ently the most effective therapy to limit infarct size, reperfu-
sion alone is inadequate to salvage the damaged myocardium
and may result in myocardial ischemia/reperfusion (IR)
injury, which is characterized by excessive oxidative stress
and inflammatory response [1–3]. In fact, as shown by both
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preclinical and clinical studies, the excess myocardial cell
death resulting from the restoration of blood and oxygen
supply can contribute up to 50% of the final infarct size [1–3].
In clinical practice, P2Y12 adenosine disphosphate
(ADP) receptor antagonists are standard of care in AMI
patients undergoing primary percutaneous intervention. Sev-
eral preclinical studies have convincingly shown that these
drugs significantly protect against IR injury, suggesting that
these pleiotropic effects could be even more important than
their antiaggregant properties in this specific clinical setting
[4–8]. Clinical trials have shown that the nonthienopyridine
P2Y12 antagonists such as Ticagrelor and Cangrelor were
associated to lower incidence of cardiovascular mortality,
AMI, or stroke compared with the thienopyridine P2Y12
antagonists, Clopidogrel and Prasugrel [9]. These differences
have been ascribed, at least in part, to better and more consis-
tent pharmacokinetic profile of the nonthienopyridine
P2Y12 antagonists (Ticagrelor and Cangrelor) that do not
require hepatic P450-mediated metabolic conversion of the
prodrug (e.g., Clopidogrel and Prasugrel) into active forms
to ensure P2Y12 receptor inhibition. Moreover, Ticagrelor
is the only P2Y12 antagonist that increases tissue adenosine
levels via inhibition of the equilibrative nucleoside trans-
porter 1 (ENT1) by protecting the extracellular adenosine
from intracellular metabolism [10–12]. This effect has been
suggested to further contribute to the drug-induced cardio-
protection [13–15], despite a recently published paper cloud-
ing this hypothesis [8].
Although different cell types (including endothelial cells
[16]) express P2Y12 receptors, the conditioning effect of
P2Y12 receptor-inhibitors has been attributed to the modu-
lation of platelet sphingosine kinase activity and perhaps to
sphingosine 1-phosphate (S1P) release [5, 17]. Since P2Y12
antagonists reduce infarct size but do not eliminate it, some
other processes must be responsible of residual IR injury.
Indeed, additive cardioprotective effects have been demon-
strated by the combination of Ticagrelor and Rosuvastatin
[13]. More recently, Audia et al. [4] demonstrated that a
highly selective caspase-1 inhibitor provides additional and
sustained infarct size reduction when added to Ticagrelor in
preclinical models of IR injury. Caspase-1 activation is a crit-
ical choke point for eliciting activation of the inflammatory
cascade NLRP3 (NOD-like receptor family, pyrin domain-
containing3) inflammasome. The NLRP3 inflammasome is
a large multimeric protein complex which interacts with an
apoptosis-associated speck-like protein including a caspase
recruitment domain (ASC), thus recruiting and activating
caspase-1, which in turn mediates the cleavage of inactive
prointerleukin- (IL-) 1? and IL-18 into their active forms
[18]. We and others have previously demonstrated the piv-
otal role of the NLRP3 inflammasome in cardiometabolic
disorders, including myocardial ischemia reperfusion injury,
[19–23] and several NLRP3 inhibitors, including the small
molecule INF we recently developed, have been tested in
animal model of IR injury, showing salvage of part of the
myocardium at risk [24, 25]. The cardioprotective role of
NLRP3 inhibitors is attributable, at least in part, to their abil-
ity to modify protective pathways and redox environment of
cells [24, 26].
In the present study, we evaluate (1) the ability of Tica-
grelor and INF, alone and in combination, to reduce infarct
size following IR injury, (2) the potential mechanisms of
cross-talk between the two drug treatments underlying their
myocardial protection, and (3) the relevance of the presence
of blood in mediating cardioprotective effects and the platelet
mediators released after Ticagrelor exposure.
2. Materials and Methods
2.1. Ex Vivo Rat Model of Heart IR Injury. Male Wistar rats
(Harlan Laboratories, Udine, Italy) 5–6 months old, reaching
a body weight of 450–550 g, were anesthetized with sodium
pentothal (50mg/kg) by intraperitoneal injections and hepa-
rinized (800U/100 g b.w., i.m.) before being culled by cervical
dislocation. The hearts were then rapidly excised, placed in
an ice-cold buffer solution, and weighed. The excised hearts
were rapidly perfused by the Langendorff technique with
Krebs-Henseleit bicarbonate buffer containing (mM) NaCl
118, NaHCO3 25, KCl 4.7, KH2PO4 1.2, MgSO4 1.2, CaCl2
1.25, and Glucose 11. The buffer was gassed with 95%
O2 : 5% CO2. The hearts were perfused in constant flowmode
to achieve a perfusion pressure of about 80mmHg. To assess
the conditions of experimental preparation, coronary perfu-
sion pressure was monitored during all experiments [27],
and flow rate was checked in a specific time period. The tem-
perature of the perfusion system was maintained at 37°C.
After a 30min stabilization period, the hearts were subjected
to a protocol of IR, which consisted in 30min of global no-
flow, normothermic ischemia followed by a period of
60min of reperfusion. At the end of perfusion period, the
hearts were rapidly removed from the perfusion apparatus
and divided in two parts by a coronal section (perpendicular
to the long axis). The apical part of the left ventricle (LV, less
than 1/3 of ventricular mass) was frozen rapidly in liquid
nitrogen and stored at -80°C and subsequently used for
Western blot analysis; the basal part of the LV was used for
infarct size assessment.
The protocol was approved by the Institutional Animal
Care and Use Committee of the University of Turin and con-
formed to the European Directive 2010/63/EU on the protec-
tion of animals used for scientific purposes.
2.2. Drug Treatments. Rats (n = 6 − 8 per group) received
water or Ticagrelor (TIC, 150mg/kg/d) by oral gavage for 3
days (oTIC). Then, the isolated hearts were submitted to
ischemia/reperfusion as described above (IR and oTIC
groups). A subgroup of isolated hearts from oTIC rats were
exposed to the selective NLRP3 inflammasome inhibitor
INF (50μM) in the perfusate for 20min before ischemia
(oTIC+exINF). In a subsequent series of experiments, the
isolated hearts from control rats were pretreated with
3.70μM Ticagrelor or 50μM exINF or both in the perfusate
for 20min before ischemia (exTIC, exINF, and exTIC+exINF
groups, respectively). After stabilization, sham hearts under-
went 90min perfusion only and served as control group
(Figure 1).
A stock solution of 200mM INF in DMSO was prepared
and was then diluted at a final concentration of 50μM in the
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perfusion buffer. The description of the synthesis of the
inhibitor as well as the in vitro biological effects has been
already published. INF is an acrylate derivative originally
synthesized by Cocco et al. [28] and selected, among the
tested compounds, as the most effective inhibitor of
NLP3 activation (IC50 of 1:26 × 10−7 M and 1:58 × 10−7 M
in LPS/ATP-triggered and LPS/nigericin-triggered pyropto-
sis, respectively). As previously documented [29, 30], INF
inhibits the NLRP3 ATPase activity of isolated human-
recombinant NLRP3 protein as well as caspase-1 activation,
and it acts as covalent NLRP3 inhibitor through irreversible
binding to nucleophilic residues present in NLRP3, with a
reactivity of 0:824 ± 0:017M−1 s−1, measured as second-
order rate constant (k2) for the reaction with cysteamine.
Ticagrelor was dissolved at 3.70μM concentration in Krebs
solution. The in vivo dose of Ticagrelor and the in vitro con-
centrations of both Ticagrelor and INF were chosen accord-
ing to previous studies demonstrating their efficacy against
myocardial IR injury [13, 24, 28, 31].
2.3. Infarct Size Assessment. Infarct areas were assessed at the
end of the 60min reperfusion with the nitro-blue-
tetrazolium (NBT) technique. The basal part of the left ven-
tricle was dissected by transverse sections into two/three
slices. Following 20min of incubation at 37°C in 0.1% solu-
tion NBT (Sigma-Aldrich, St. Louis, MO, USA) in phosphate
In vivo treatments: 
oTIC groups: received Ticagrelor by oral gavage for 3 days.
Other groups: received water by oral gavage for 3 days.
Ex vivo protocols
Buff: buffer solution; stab: stabilization.
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Figure 1: Schematic representation of rat treatments in vivo and various protocols ex vivo. Rats received water or Ticagrelor (TIC) by oral
gavage for 3 days; then, hearts were isolated and perfused. After stabilization, isolated hearts were submitted to specific treatment and then
to global ischemia/reperfusion protocol.
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buffer, unstained necrotic tissue was carefully separated from
stained viable tissue by an independent observer, who was
unaware of the protocols. Since the ischemia was global and
we analyzed only the basal part of the ventricle, the necrotic
mass was expressed as a percentage of the analyzed ischemic
tissue [32].
2.4. Preparation of Tissue Extracts. As previously described
[33], the heart apex was homogenized at 10% (w/v) in a
Potter-Elvehjem homogenizer (Wheaton, NJ, USA) using a
homogenization buffer (containing 20mM HEPES, pH7.9,
1mM MgCl2, 0.5mM EDTA, 1mM EGTA, 1mM dithio-
threitol (DTT), 0.5mM phenylmethyl sulphonyl fluoride
(PMSF), 0.5% Nonidet P-40, phosphatase, and protease
inhibitors) and centrifuged at 1300 × g for 5min at 4°C. To
obtain the cytosolic fraction, supernatants were removed
and centrifuged at 16000 × g at 4°C for 40 minutes. The pel-
leted nuclei were resuspended in extraction buffer containing
20mM HEPES (pH7.9), 1.5mM MgCl2, 420mM NaCl,
0.2mM EDTA, 20% glycerol, 1mM EGTA, phosphatase,
and protease inhibitors and incubated in ice for 30 minutes
followed by centrifugation at 16000 × g for 20min at 4°C.
The resulting supernatants containing nuclear proteins were
carefully removed, and protein content was determined on
both nuclear and cytosolic extracts using the bicinchoninic
acid (BCA) protein assay following the manufacturer’s direc-
tions (Therma Fisher Scientific, Rockford, IL). Protein
extracts were stored at −80°C until use.
2.5. Determination of IL-1β in Heart Homogenates.Commer-
cially available ELISA kit (R&D Systems, Abingdon, UK) was
used to measure concentrations of IL-1β in tissue homoge-
nates, according to the manufacturer’s instructions.
2.6. Western Blot Analysis. Equal amounts of total protein
extracts were separated by SDS-PAGE and electrotransferred
to nitrocellulose membrane (GE-Healthcare Europe, Milan,
Italy). Membranes were probed with rabbit anti-NLRP3
(Abcam, Cambridge, UK), rabbit anti-caspase-1 (Santa Cruz
Biotechnology, Dallas, TX, USA), mouse anti-Ser473Akt (Cell
Signaling Technology, Danver, MA, USA), rabbit anti-total
Akt (Cell Signaling Technology, Danver, MA, USA), rabbit
anti-Ser9 GSK-3β (Abcam, Cambridge, UK), anti-total
GSK-3β (Cell Signaling Technology, Danver, MA, USA),
anti-Ser660 PKC and total PKC (Santa Cruz Biotechnology,
Dallas, TX, USA), SOD2 (Novus Biologicals, Centennial,
CO, USA), and NRF2 (Thermo Fisher Scientific, Whaltam,
MA, USA) followed by incubation with appropriate HRP-
conjugated secondary antibodies (BioRad). Proteins were
detected with ClarityWestern ECL substrate (BioRad, Califor-
nia, USA) and quantified by densitometry using analytic soft-
ware (Quantity-One, BIO-RAD Image Lab Software.6.0.1.).
Results were normalized with respect to densitometric value
of mouse anti-tubulin (Abcam, Cambridge, UK), and autora-
diograms showing statistically significant differences in terms
of gel-loading homogeneity were excluded from the following
biomarkers analyses.
2.7. Platelet Release of S1P and Adenosine. Fasting venous
blood sample from four male healthy volunteers (mean age:
38 ± 2 years) was withdrawn without stasis and anticoagu-
lated with citrate-dextrose solution (ACD, with the final
ACD/blood ratio 1: 6 vol/vol). The human platelet study
was authorized by “Comitato Etico Interaziendale San Luigi
Gonzaga,” authorization n. 155/2017, and informed consent
was obtained in accordance with the 1964 Declaration of
Helsinki and its later amendments. The platelet-rich plasma,
obtained by centrifugation at 100 × g for 20min, underwent
further centrifugation at 2000 × g for 10min, and pellet was
washed 2 times at 37°C in HEPES-Na buffer (mmol\L):
10 HEPES Na, 140 NaCl, 2.1 MgSO4, 10 D-glucose, and
pH7.4. Platelets were counted by automatic blood cells
counter (Mythic 18, Orphèe, Switzerland) and resuspended
to a final concentration of 2 × 1011 cells/L in phosphate-
buffered saline containing 1% BSA. The contamination of
white blood cells was less than 1/104 platelets. Platelet sam-
ples were subjected to stirring (1200 rpm speed at 37°C) in
both the absence and presence of Ticagrelor (5000 ng/mL,
30min) or thrombin receptor-activating peptide (TRAP-6)
(Mascia Brunelli, Monza, Milan, Italy) (10μmol/L, 8min),
then centrifuged at 4000 rpm for 10min. Supernatants
were stored at -20°C until sphingosine, S1P, and adenosine
measurements.
2.8. Sample Preparation for UHPLC-Tandem Mass Analysis.
100μL of platelet samples and heart homogenates were
added with 2mL of 0.1% trifluoroacetic acid in chloroform/-
methanol 1/1 and with internal standards (adenosine and
S1P d7) at 300μg/L as final concentration. After vortex in g
for 30 seconds, 0.5mL of chloroform and 0.5mL of water
were added. After centrifugation, organic phase was recov-
ered and extracted twice with 1mL of chloroform. The solu-
tion was dried overnight under vacuum (Centrivap,
Labconco, Kansas City, MO, USA) and reconstituted with
100μL of eluents A/B 7/3.
2.9. UHPLC-Tandem Mass Analytical Method. The analyses
of sphingolipids and adenosine were performed using a Nex-
era (Shimadzu, Milan, Italy) UHPLC coupled through an ESI
source to a Qtrap5500 triple quadrupole analyzer (Sciex,
Milan, Italy).
The chromatographic separation was achieved with a
Kinetex column (1.7μm, 100 × 2:1mm, 100Å, Phenomenex,
Bologna, Italy) with 0.1% formic acid in water/acetonitrile
8/2 (eluent A) and 0.1% formic acid in isopropanol/acetoni-
trile 8/2 (eluent B). The separation gradient was from 5 to
100% of B in 7 minutes, followed by column reconditioning.
Flow rate was set at 400μLmin-1, and injection volume was
3μL. The LC column effluent was delivered to the ESI ion
source, using air as both 1 and 2 gasses (40 and 50 arbitrary
units, respectively), and the ion voltage was 5.0 kV. Curtain
gas (nitrogen) was 30 arbitrary units.
The multiple reaction monitoring (MRM) transitions
and parameters were C18-Sph (m/z) 300@282 CE 13 V;
C18-S1P (m/z) 380@264 CE 21 V; and adenosine (m/z)
268@136 CE 21 V. For the internal standard, the MRM tran-
sition was C18-S1P d7 (m/z) 387@271 CE 19 V. The lower
limit of detection (LLOQ) was 0.50μg/L for all analytes.
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2.10. Materials. Unless otherwise stated, all compounds were
purchased from the Sigma-Aldrich Company Ltd. (St. Louis,
Missouri, USA).
2.11. Statistical Analysis. All values are expressed as means
± SEM and were analyzed by ANOVA test followed by Bon-
ferroni’s posttest and Student’s t-test. A P value < 0.05 was
considered statistically significant.
3. Results
3.1. Infarct Size Was Reduced by Ticagrelor In Vivo but Not
Ex Vivo. Rat hearts exposed to a 30min global ischemia
and 60min reperfusion developed infarction which was
69:5 ± 2:3% of ischemic area at risk (AAR). Infarct size was
significantly reduced by rat pretreatment for 3 days with
Ticagrelor (oTIC, infarct size 49:6 ± 3:9% of AAR, P < 0:01
vs. IR group). No protective effects were recorded when Tica-
grelor was added ex vivo to the perfusate of excised hearts
from untreated animals (exTIC, infarct size 68:6 ± 3:0% of
AAR), thus suggesting that Ticagrelor protection was only
triggered in the intact organism (Figure 2). Coronary flow
and perfusion pressure measured during stabilization in the
IR group (10 ± 1mL/min/g and 80 ± 2mmHg, respectively)
were not statistically different from those recorded in the
treated groups, thus suggesting similar oxygen demands
among groups.
3.2. Ticagrelor and INF Do Not Exert Additive Effects on
Infarct Size Limitation. When INF was added ex vivo to the
perfusate before ischemia (exINF), we observed a significant
reduction in infarct size (exINF, infarct size 38:3 ± 3:0% of
AAR, P < 0:05 vs. IR group), comparable to the one achieved
by oTIC alone (Figure 2).
Interestingly, exINF did not exert additive effects on pro-
tection against infarct size evoked by oral Ticagrelor pretreat-
ment, as the reduction in infarct size evoked by the
combination was almost identical to that obtained herein
with either Ticagrelor or exINF alone (oTIC+exINF, infarct
size 44:1 ± 1:9% of AAR, P < 0:05 vs. IR group). Similarly,
no priming effects on exINF protection were recorded when
Ticagrelor was coadministered ex vivo in the perfusate only
(exTIC+exINF, infarct size 52:2 ± 2:7% of AAR).
3.3. Ticagrelor Pretreatment Prevented NLRP3 Inflammasome
Activation and Downstream Signaling. Expression level and
activation of the downstream signaling of NLRP3 inflamma-
some were assessed by Western blotting analysis in protein
extracts obtained from the apical portion of hearts pretreated
or not with either Ticagrelor or INF and exposed to IR.
As expected, the INF pretreatment effectively reduced the
IR-induced NLRP3 upregulation and activation, resulting in
significant reduction of the cleaved active p10 subunit of
caspase-1 (Figures 3(a) and 3(b)). As a consequence of
reduced caspase-1 activation, the levels of IL-1β, that reached
the highest concentrations after 60min of reperfusion,
showed a mild but still significant decrease in the exINF
group (Figure 3(c)). Notably, both Western blotting analysis
and ELISA assay demonstrated that similar inhibition of
NLRP3 expression and activation could be reached when rats
were pretreated with Ticagrelor (oTIC), but not when Tica-
grelor was added in the perfusate only (exTIC). Besides, no
further NLRP3 inflammasome inhibition was recorded when
INF was added in the perfusate of heart from rats previously
exposed to Ticagrelor pretreatment (oTIC+exINF).
3.4. Risk Pathway Protective Activity Was Enhanced by Either
Oral Ticagrelor Pretreatment Or INF Heart Exposure. Since
RISK pathway is activated by both pre- and postconditioning
treatments [34], we quantified expression and activity (in
terms of phosphorylation) of its key members. After 60min
of reperfusion, slight but not significant increase in phos-
phorylation rate of Akt, GSK-3β, and PKC (Figures 4(a)–
4(c), respectively) was recorded in untreated hearts exposed
to IR protocol, when compared to the sham group. The phos-
phorylation rates of Akt, GSK-3β, and PKC induced by the
60min reperfusion were all increased massively in oTIC
and exINF (both P < 0:05 vs. sham; P = NS among groups).
No additive effects were recorded when the two treatments
were combined. Interestingly, ex vivo Ticagrelor exposure
20min prior to ischemia only did not significantly modify
the activation of the RISK pathway evoked by IR and/or INF.
3.5. Ticagrelor and INF Improved IR-Induced Antioxidant
Response. SOD2 is an important endogenous antioxidant
and provides protection against myocardial IR. Consistently
with other studies [24], we found that IR led to increased
expression of SOD2 (P < 0:05 vs. sham). All treatments
blunted IR-induced SOD upregulation. However, in oTIC,
oTIC+exINF, and exTIC+exINF groups, the levels of SOD2
were significantly lower than that of IR group (P < 0:05 vs.
IR, Figure 5(a)). A reduction in SOD2 levels was also
recorded in the heart of mice treated with INF only when
compared to IR group, without reaching statistical signifi-
cance (Figure 5(a)).
The Western blot analysis on the expression levels of the
antioxidant transcription factor Nrf2 showed that its nuclear
translocation was reduced by IR when compared to sham
(Figure 5(b)). All treatments blunted IR-induced reduction















oTIC oTIC+exINF exTIC exTIC+exINF exINF
Figure 2: Infarct size. Data analyzed by one-way ANOVA followed
by a Bonferroni post hoc test and expressed as mean ± SEM. n = 6
– 8 per group. Statistical significance: ●P < 0:05 vs. IR and
■P < 0:05vs. exTIC.
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levels of Nrf2 nuclear translocation were significantly higher
than in IR and similar to sham (Figure 5(b)).
3.6. Oral Ticagrelor Pretreatment Resulted in S1P and
Adenosine Overaccumulation in the Heart. As shown in
Figure 6, a marked increase in the myocardial concentration
of either S1P or adenosine was recorded in the postischemic
heart from rats exposed to the oral Ticagrelor pretreatment
(oTIC) when compared to IR only, whereas ex vivo adminis-
tration of Ticagrelor or exINF did not significantly affect
their levels. Combining Ticagrelor and INF (oTIC+exINF)
did not further increase S1P or adenosine accumulation in
the heart in comparison to oTIC alone.
3.7. Ticagrelor Enhanced S1P and Adenosine Release from
Platelets. Sphingosine, S1P, and adenosine were evaluated
in the supernatant of human platelet samples subjected to
stirring (1200 rpm speed at 37°C) with or without Ticagrelor
(5000ng/mL, 30min) (Table 1). Ticagrelor-treated samples
show high level of S1P in the supernatant and low level of
sphingosine if compared to control (P < 0:05). Adenosine
concentration increased significantly compared to control
in the supernatant of Ticagrelor-treated platelets. The posi-
tive control was obtained by incubating human platelet with
TRAP-6 (10μmol/L, 8min). The values of the release of S1P
and adenosine in the supernatant in TRAP-6 group were sig-
nificantly higher than control and Ticagrelor-treated plate-
lets (data not shown).
4. Discussion
The present study further extends previous findings on Tica-
grelor cardioprotective effects, confirming that the protection
was dependent upon its administration in vivo, as adding the
P2Y12 antagonist ex vivo to the perfusate in excised hearts
does not counteract the IR injury. Here, we confirm our pre-
vious data [24] that the specific and direct inhibition of
NLRP3 by exINF results in a significant reduction in infarct
size. Most notably, adding INF just before ischemia does not
further improve cardioprotection induced by Ticagrelor pre-
treatment (3 days), with no significant effect of the combina-
tion over each drug alone. We then aimed to assess whether
Ticagrelor primes the isolated hearts exposed to the inflamma-
some inhibitor. Administration of Ticagrelor to the perfusate
ex vivo does not enhance the heart response to exINF, showing
no interactions between the two treatments.
Indeed, Ticagrelor has been shown to modulate the
expression on blood cells of toll-like receptors, key receptors
involved in NLRP3 regulation [35]. Here, we show that the
reduction in infarct size achieved by oral Ticagrelor is, at least
in part, attributable to a cardioprotective effect mediated by
the inhibition of the NLRP3 inflammasome pathway, as simi-
lar inhibitory effects on the activation of pivotal markers of the
inflammasome cascade were recorded when either pharmaco-
logical tools (oral Ticagrelor or exINF) were used. With these
two treatments, there is also an upregulation of the RISK path-









































































Sham IR oTIC oTIC+exINF exTIC exTIC+exINF exINF
(c)
Figure 3: Western blotting analysis on (a) NLRP3, (b) pro- and activated caspase, and (c) quantification of IL1β by ELISA kit assay. Data
analyzed by one-way ANOVA followed by a Bonferroni post hoc test and expressed as mean ± SEM. n = 6 – 8 per group. Statistical
significance: ●P < 0:05 vs. IR; ★P < 0:05 vs. sham, ■P < 0:05 vs. exTIC. Representative blots are shown of at least three different experiments.
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To the best of our knowledge, so far, only another study
has suggested that cardioprotection of Ticagrelor tested in
models of acute myocardial injury can be partially attribut-
able to inhibition of mRNA levels of NLRP3 and IL-1beta
in the heart of diabetic rats [13]. Here, we extended these

















































































Sham IR oTIC oTIC+exINF exTIC exTIC+exINF exINF
(c)
Figure 4: Western blotting analysis on (a) Akt, (b) GSK3β, and (c) PKC. Data analyzed by one-way ANOVA followed by a Bonferroni post
hoc test and expressed as mean ± SEM. n = 6 – 8 per group. Statistical significance: ●P < 0:05 vs. IR; ★P < 0:05 vs. sham, ■P < 0:05 vs. exTIC.



















































Sham IR oTIC oTIC+exINF exTIC exTIC+exINF exINF
(b)
Figure 5: Western blotting analysis on (a) SOD2 and (b) nuclear and cytosolic Nrf2. Data analyzed by one-way ANOVA followed by a
Bonferroni post hoc test and expressed as mean ± SEM. n = 6 – 8 per group. Statistical significance: ●P < 0:05 vs. IR; ★P < 0:05 vs. sham,
■P < 0:05 vs. exTIC. Representative blots are shown of at least three different experiments.
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that Ticagrelor, when administered to rats in vivo, evokes sig-
nificant decrease of protein levels of NLRP3, resulting in lower
activation of caspase-1, thus counteracting the IR-induced
accumulation of active IL-1beta proteins in the heart.
A pharmacological approach with cardioprotective
inhibitors has suggested that cardioprotection induced by
P2Y12 antagonists is due to a conditioning phenomenon















































Sham IR oTIC oTIC+exINF exTIC exTIC+exINF exINF
(c)
Figure 6: Myocardial levels of sphingosine, sphingosine 1P (S-1P), and adenosine. Data analyzed by one-way ANOVA followed by a
Bonferroni post hoc test and expressed as mean ± SEM. n = 6 – 8 per group. Statistical significance: ●P < 0:05 vs. IR; ★P < 0:05 vs. sham,
■P < 0:05 vs. exTIC.
Table 1: Level of sphingosine, sphingosine 1P (S-1P), and adenosine released by platelets exposed to Ticagrelor.
Sphingosine (ng/mL) S-1P (ng/mL) Adenosine (ng/mL)
Control 356:9 ± 44:3 94:3 ± 29:0 18:8 ± 5:8
Ticagrelor 68:4 ± 2:4∗ 300:7 ± 38:5∗ 48:8 ± 5:4∗
Level of sphingosine, S-1P, and adenosine, measured with UHPLC-tandem mass analysis, in the supernatant of human platelet subjected to stirring (1200 rpm
speed at 37°C) incubated in absence and presence of Ticagrelor (5000 ng/mL, 30min). Data analyzed by Student’s t test and expressed as mean ± SEM; n = 6 − 8
per group in duplicate. Statistical significance: ∗P < 0:05 vs. control.
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sphingosine kinase inhibitor, Cangrelor’s antiplatelet effect
seems intact; nevertheless, in vivo studies did not definitively
rule out a contribution from the antiplatelet effect in limiting
IR injury. Our study, in which the P2Y12 antagonist was
administered in vivo and myocardial infarct subsequently
induced ex vivo, in the absence of platelets, definitively con-
firms that the protective effect is mainly due to a precondi-
tioning effect in vivo that lasts throughout the IR procedure
ex vivo. The lack of cardioprotection by Ticagrelor when
administered in the ex vivo model further support the idea
of a blood cell-mediated preconditioning effect [5, 8, 31].
Given the apparent dependence upon the presence of blood
in mediating Ticagrelor effects [5, 17], it would seem logical
to propose that the cardioprotective effect of Ticagrelor is
dependent on platelets and likely the P2Y12 receptor. This
is supported by previous observations showing that chemi-
cally distinct P2Y12 antagonists have similar cardioprotec-
tive properties [6, 16, 17]. We thus investigated the ability
of Ticagrelor to affect platelet ability to release S1P, an essen-
tial, bioactive lysophospholipid mediator that regulates vari-
ous physiological functions such as lymphocyte trafficking,
inflammation, and behavioural characteristics of the vascular
system [36]. Platelets are among the major source of S1P in
the circulation [17, 37], and platelet-derived S1P has been
demonstrated to exert a critical role in the repair of pivotal
microvascular structures during injury [38, 39]. Ticagrelor
is unique in being an inhibitor of equilibrative nucleotide
transporter 1 (ENT1) [6, 13, 14, 16]. Here, we confirm these
effects in isolated human platelets, as revealed by an increase
in S1P and adenosine release after exposure to Ticagrelor.
Ticagrelor was previously demonstrated to raise tissue levels
of adenosine, which is a known endogenous cardioprotective
substance in pathophysiological conditions of the heart,
including myocardial ischemia and heart failure [40, 41].
This effect has been suggested to involve inhibition of
ENT1 in heart tissue [13–15]. However, so far, no experi-
mental evidence of direct effects of Ticagrelor on ENT1 has
been reported. Besides, our findings on the lack of cardiopro-
tection by Ticagrelor on the isolated heart cloud this hypothe-
sis of cardioprotection through interference with cardiac ENT
1 [8]. Thereby, its effects on increasing adenosine levels in
heart tissue could derive from an effect of Ticagrelor on a sub-
group of blood cells. Both erythrocytes and platelets are
known to release different substances in blood stream, includ-
ing adenosine and S1P [17, 42, 43]. Here, we demonstrated for
the first time that Ticagrelor increased the levels of adenosine
released from platelets, thus suggesting that this effect might
contribute, together with S1P, to the cardioprotection
recorded when Ticagrelor was administered in vivo only.
The contribution of blood-derived S1P and adenosine in
mediating the myocardial protective effects of Ticagrelor was
confirmed by showing that both S1P and adenosine reached
the highest concentrations in the heart of rats orally exposed
to Ticagrelor. While the increase in myocardial adenosine
levels has been already documented in the IR heart of rats
orally pretreated with Ticagrelor [13], so far, no direct myo-
cardial detection of S1P or comparison of adenosine/S1P
myocardial levels between in vivo vs. ex vivo treatments has
been reported in the literature. Thus, our study adds a further
interesting piece of evidence on the ability of Ticagrelor to
cause blood cells to release substances, which may contribute
to cardioprotection. In fact, either S1P or adenosine has been
already demonstrated to evoke protective effects throughout
activation of the protective survival RISK pathway in the
heart [44, 45]. As Ticagrelor protection seems to depend
at least in part on the same signaling cascade modulate
S1P and adenosine, it seemed likely that these endogenous
components would be involved in Ticagrelor’s protective
mechanism. Interestingly, both the treatment (Ticagrelor
and exINF) in aerobic conditions do not affect myocardial
perfusion, thus suggesting an unchanged oxygen demand
in comparison to untreated hearts. Moreover, the levels of
components of either NLRP3 or RISK pathways in sham ani-
mals were lower than those detected in all IR groups (pro-
tected and nonprotected), thus suggesting that in aerobic
conditions, the pharmacological treatments do not influence
the myocardial metabolism, but may trigger mechanisms
that will make the hearts more resistant to IR challenge
boosting RISK activation in postischemic phase. Indeed, the
RISK pathway is an intrinsic prosurvival signaling cascade
evoked by IR itself which confers protection against the
reperfusion insult by avoiding the opening of the mitochon-
drial permeability transition pore at the onset of reperfusion
[34, 46]. Potentiation of RISK activation in the early minutes
of reperfusion contributes to cardioprotection induced by
preconditioning protocols. Actually, in protected hearts, the
phosphorylation of RISK enzymes peaks at 10-15minutes
of reperfusion and progressively wanes thereafter [34, 47–
49]. A two-threefold higher phosphorylation level after
60min of reperfusion is a strong indication of kinase involve-
ment in protection, especially if we consider that the reduc-
tion in infarct size in protected hearts resulted in a ~20%
increase in vital tissue when compared to control IR hearts.
As previously documented [6], pharmacological inhibition
of the RISK pathway blunted the protective effects of P2Y12
antagonists against IR, thus further supporting the hypothe-
sis that their mechanisms of cardioprotection utilize specific
signal transduction of myocardial protection rather than
inhibition of intravascular coagulation. Our study extends
these findings confirming cross-talk mechanisms linking
NLRP3 inflammasome to RISK pathway in cardioprotection,
which have been so far faintly suggested [50–52], but not
convincingly demonstrated. Besides, it shows that Ticagrelor
uses similar mechanisms of protection evoked by a NLRP3
inflammasome inhibitor, leading to activation of the RISK
pathway. The lack of additive effects of the drug combination
may be explained considering that additional protection can-
not be induced by strategies that share common prosurvival
signaling pathways such as the P2Y12 antagonist and the
NLRP3 inflammasome inhibitor. However, previous studies
demonstrated that treatment with a caspase-1 inhibitor prior
to ischemia or reperfusion adds its protection to the one elic-
ited by the P2Y12 antagonist, Cangrelor [4, 7]. Differently
from INF that directly targets NLRP3 complex formation,
direct caspase-1 inhibitors may influence not only inflamma-
tory response but also glycolytic, mitochondrial, and pyrop-
totic cell death [4]; thus, the additional beneficial effects
recorded by these authors could be due to interference with
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any of these pathways beyond the inhibition of the NLRP3
inflammasome-caspase axis. Another substantial difference
between our study and that of Audia et al. [4] is that these
authors had higher coronary flow when the caspase-1 inhib-
itor was used, while we perfused the hearts at constant flow,
to avoid flow effects on IR injury.
The role of oxidative stress in contributing to IR injury is
not clear [53, 54]. Overall, it seems that IR-dependent oxida-
tive stress is reduced by all protective treatments. However,
only Ticagrelor pretreatment displays a consistent effect in
limiting the oxidative component as suggested by the signif-
icant increase in nuclear levels of Nrf2 and by the downregu-
lation of SOD2. Nevertheless, also for this mechanism, there
are not apparent differences between Ticagrelor and INF.
Moreover, the antioxidant effect of Ticagrelor given orally
seems stronger than that observed when it is given ex vivo.
5. Limitation of the Study
Our results confirm Ticagrelor conditioning effects, which
are not additives to the cardioprotection achieved by directly
inhibiting NLRP3. It is likely that this lack of additive effect is
due to the activation of RISK pathway by both treatments.
Other studies demonstrated additive effect when P2Y12 and
a downstream NLRP3 factor, namely, caspase-1, were inhib-
ited [4, 7], thus confirming that the cross-talk between
NLRP3 and RISK cardioprotective pathways is quite complex
[36]. Besides, here, we did not test the impact of the proposed
pharmacological treatments on the tested signaling cascades
at basal condition. Therefore, further studies are needed to
fully elucidate the cross-talk among mechanisms linking
NLRP3 complex, redox state, and RISK pathway. Finally,
we must consider that all experimental paradigms have dis-
advantages and advantages. For instance, we used gavage to
administer Ticagrelor instead of a spontaneous intake which
is more physiological, as gavage guarantees a more constant
dosage, which is recommendable in cardioprotection studies
[55]. Determining which blood-derived factors mediate
Ticagrelor-induced cardioprotection was beyond the scope
of this study. Nevertheless, the fact that Ticagrelor increases
platelet release of both adenosine and S1P suggests these fac-
tors as important players that deserve further investigations.
6. Conclusions
In conclusion, we confirm that Ticagrelor requires the pres-
ence of blood to act as conditioning agent. Importantly, we
demonstrate that the cardioprotective effects of Ticagrelor
are not due to a direct action on the myocardial tissue nor
to its antiaggregating effect, whereas the NLRP3 inhibitor,
INF, is able to act directly on the heart. Nevertheless, these
two drugs given before ischemia activate a similar protective
pathway, involving RISK pathway and redox modulation,
without additive cardioprotective effects.
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